Fortis Malar

When is the next results date for Fortis Malar?

No Upcoming Board Meetings

Has Fortis Malar declared dividend?

Yes, Fortis Malar Hospitals Ltd has declared a 25% dividend, amounting to ₹2.5 per share, with an ex-date of July 24, 2024. The company has demonstrated strong total returns across various periods, with a 5-year total return of 147.51%.

Fortis Malar Hospitals Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 2.5<BR>- Ex-date: 24 Jul 24<BR><BR>Dividend Yield: 3.36%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 17.45%, with a dividend return of 0%, resulting in a total return of 17.45%.<BR><BR>Over the past year, the price return was 32.75%, the dividend return was 4.05%, leading to a total return of 36.8%.<BR><BR>In the 2-year period, the price return was 43.73%, with a dividend return of 78.49%, culminating in a total return of 122.22%.<BR><BR>For the 3-year period, the price return was 39.14%, the dividend return was 79.44%, which resulted in a total return of 118.58%.<BR><BR>In the last 4 years, the price return was 13.67%, with a dividend return of 64.59%, giving a total return of 78.26%.<BR><BR>Over the 5-year period, the price return was 60.24%, the dividend return was 87.27%, leading to a total return of 147.51%.<BR><BR>Overall, Fortis Malar has not only declared a dividend but has also shown strong total returns across various periods, indicating positive performance in both price appreciation and dividend distribution.

Who are the peers of the Fortis Malar?

Fortis Malar's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, and others. Fortis Malar has below average management risk and growth, with a 1-year return of 26.30%, lower than Fortis Health's 60.01% but higher than Global Longlife's -9.79%.

Peers: The peers of Fortis Malar are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Shanmuga Hos., Global Longlife, KK Shah Hospital, and Sangani Hospital.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, and Aatmaj Health, while Good management risk is found at Global Health. Average management risk is present at Fortis Health. and Global Longlife, while Below Average management risk is noted at Fortis Malar, Shanmuga Hos., KK Shah Hospital, and Sangani Hospital. Growth is Excellent at Max Healthcare and Apollo Hospitals, Good at Fortis Health. and Narayana Hrudaya, while Below Average growth is seen at Fortis Malar, Shanmuga Hos., Global Longlife, KK Shah Hospital, and Sangani Hospital. Capital Structure is Excellent at Max Healthcare and Global Health, Good at Fortis Health. and KK Shah Hospital, while Below Average capital structure is noted at Fortis Malar, Global Longlife, and Sangani Hospital.<BR><BR>Return Snapshot: Fortis Health. has the highest 1-year return at 60.01%, while Global Longlife has the lowest at -9.79%. Fortis Malar's 1-year return of 26.30% is lower than Fortis Health.'s but higher than Global Longlife's. Additionally, Shanmuga Hos. and Global Longlife have negative six-month returns.

Should I buy, sell or hold Fortis Malar?

Is Fortis Malar overvalued or undervalued?

As of April 25, 2023, Fortis Malar is considered a risky investment due to its high PE ratio of 139.64, negative profitability metrics, and poor return on capital employed, despite outperforming the Sensex year-to-date.

As of 25 April 2023, Fortis Malar's valuation grade has moved from does not qualify to risky, indicating a shift in its perceived investment quality. The company appears to be overvalued, given its high PE ratio of 139.64 and a negative EV to EBIT and EV to EBITDA of -56.94, which suggest significant concerns regarding profitability. Additionally, the return on capital employed (ROCE) stands at -17.23%, further highlighting operational inefficiencies.<BR><BR>In comparison to its peers, Fortis Malar's valuation metrics are considerably higher, with Max Healthcare at a PE of 100.29 and Apollo Hospitals at 69.03, both of which are more reasonably valued. The PEG ratio for Fortis Malar is 1.33, which, while not excessively high, does not compensate for the other concerning ratios. Notably, Fortis Malar has outperformed the Sensex year-to-date with a return of 22.85% compared to the Sensex's 5.63%, but this does not mitigate the overall valuation concerns.

What is the technical trend for Fortis Malar?

As of May 28, 2025, Fortis Malar's trend is mildly bullish, supported by moving averages and Bollinger Bands, despite mixed signals from the MACD and uncertainty indicated by Dow Theory.

As of 28 May 2025, the technical trend for Fortis Malar has changed from bullish to mildly bullish. The weekly MACD indicates a mildly bearish stance, while the monthly MACD remains bullish, suggesting mixed signals. The Bollinger Bands show a mildly bullish trend on both weekly and monthly time frames, and daily moving averages also reflect a mildly bullish outlook. The KST is bullish on both weekly and monthly charts, reinforcing some positive momentum. However, Dow Theory indicates no trend on both weekly and monthly time frames, suggesting uncertainty. Overall, the current stance is mildly bullish, driven primarily by the moving averages and Bollinger Bands, despite some bearish signals from the weekly MACD.

Who are in the management team of Fortis Malar?

As of March 2023, the management team of Fortis Malar includes Daljit Singh (Chairman), Chandrasekar Ramasamy (Whole Time Director), and several independent directors: Ramesh L Adige, Ravi Rajagopal, and Shailaja Chandra, along with Sandeep Singh (Company Secretary & Compliance Officer).

As of March 2023, the management team of Fortis Malar includes the following individuals:<BR><BR>1. Ramesh L Adige - Independent Director<BR>2. Daljit Singh - Chairman & Non Executive Director<BR>3. Ravi Rajagopal - Independent Director<BR>4. Shailaja Chandra - Independent Director<BR>5. Chandrasekar Ramasamy - Whole Time Director<BR>6. Sandeep Singh - Company Secretary & Compliance Officer<BR><BR>These members play various roles in the governance and operational management of the company.

What does Fortis Malar do?

Fortis Malar Hospitals Ltd operates a multi-specialty hospital and reported a net profit of 4 Cr for March 2025, with a market cap of INR 133 Cr. Key metrics include a P/E of 133.00, a dividend yield of 3.57%, and a return on equity of 1.32%.

Overview:<BR>Fortis Malar Hospitals Ltd operates a multi-specialty hospital and belongs to the micro-cap category within the hospital industry.<BR><BR>History:<BR>The company was incorporated on April 12, 1989, originally as Malar Hospital Limited. It changed its name to Fortis Malar Hospital Limited on December 21, 2010. The most recent quarterly results reported net profit for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 4 Cr (Quarterly Results - Mar 2025)<BR>Market-cap value: INR 133 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 133.00<BR>Industry P/E: 59<BR>Dividend Yield: 3.57%<BR>Debt Equity: -0.59<BR>Return on Equity: 1.32%<BR>Price to Book: 4.34<BR><BR>Contact Details:<BR>Address: Fortis Hospital Sector-62, Phase-VIII Mohali Punjab : 160062<BR>Phone: +91-172-5096001<BR>Email: secretarial.malar@malarhospitals.in<BR>Website: http://www.fortismalar.com

Who are the top shareholders of the Fortis Malar?

The top shareholder of Fortis Malar is Fortis Hospitals Limited, holding 62.71% of the shares, while individual investors collectively own 29.53%. Ruckmani Natarajan is the largest public shareholder with a 2.07% stake.

The top shareholders of Fortis Malar include Fortis Hospitals Limited, which holds the majority stake at 62.71%. There are no pledged promoter holdings, and the only mutual fund investment is from one scheme, accounting for 0.07%. Notably, Ruckmani Natarajan is the highest public shareholder with a stake of 2.07%. Additionally, individual investors collectively hold 29.53% of the shares.

How big is Fortis Malar?

As of 24th July, Fortis Malar Hospitals Ltd has a market capitalization of 134.00 Cr, with reported Net Sales of 0.00 Cr and a Net Profit of 0.40 Cr in the latest four quarters. The balance sheet for March 2025 shows Shareholder's Funds of 30.21 Cr and Total Assets of 36.83 Cr.

As of 24th July, Fortis Malar Hospitals Ltd has a market capitalization of 134.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Fortis Malar reported Net Sales of 0.00 Cr and a Net Profit of 0.40 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 30.21 Cr and Total Assets of 36.83 Cr.

Are Fortis Malar latest results good or bad?

Fortis Malar's latest results show a mixed but generally positive trend, with improved profitability metrics despite a flat overall performance. While the company reported a negative Profit Before Tax, its Profit After Tax has significantly improved, surpassing last year's total within six months; however, the stock is currently rated as a 'Sell' by MarketsMOJO.

Fortis Malar Hospitals' latest financial results show a mixed but generally positive trend. While the overall performance for the quarter ending March 2025 was flat, there are notable improvements in profitability metrics. The company reported a Profit Before Tax (PBT) of Rs -0.37 crore, which, despite being negative, is the highest it has achieved in the last five quarters, indicating a consistent recovery.<BR><BR>Moreover, the Profit After Tax (PAT) for the last six months stands at Rs 0.37 crore, a significant turnaround from the previous year's PAT of Rs -3.24 crore. This suggests that Fortis Malar has already surpassed its profitability from the entire previous year within just half a year.<BR><BR>However, the stock is currently rated as a 'Sell' by MarketsMOJO, reflecting a cautious market sentiment despite the positive signs in profitability. Overall, while the results are not overwhelmingly strong, the recovery in profitability metrics indicates a positive trend for the company.

How has been the historical performance of Fortis Malar?

Fortis Malar has experienced a significant decline in financial performance, with net sales dropping from INR 144.59 crore in March 2019 to zero by March 2025, alongside severe reductions in profitability and total assets. The company faces critical liquidity challenges, highlighted by a net cash outflow of INR 107 crore in March 2025.

Answer:<BR>The historical performance of Fortis Malar shows significant fluctuations in its financial metrics over the years, culminating in a challenging situation in the most recent fiscal year.<BR><BR>Breakdown:<BR>Fortis Malar's net sales have seen a drastic decline from INR 144.59 crore in March 2019 to zero in March 2025, indicating a complete cessation of revenue generation. Total operating income followed a similar trend, dropping from INR 144.59 crore in March 2019 to zero in March 2025. The company reported an operating profit of INR 0.58 crore in March 2025, down from INR 11.21 crore in March 2023, reflecting a significant deterioration in profitability. The profit before tax also fell sharply, from INR 50.01 crore in March 2024 to INR 0.57 crore in March 2025. Consequently, the profit after tax dropped from INR 45.32 crore in March 2024 to INR 0.39 crore in March 2025. The company's total assets decreased from INR 188.33 crore in March 2020 to INR 36.83 crore in March 2025, while total liabilities also fell from INR 147.03 crore in March 2019 to INR 36.83 crore in March 2025. Cash flow analysis reveals a net cash outflow of INR 107 crore in March 2025, contrasting with a net inflow of INR 101 crore in March 2024, indicating severe liquidity challenges. Overall, the financial data reflects a troubling decline in Fortis Malar's operational and financial health over the years.

Which are the latest news on Fortis Malar?

Why is Fortis Malar Hospitals Ltd falling/rising?

As of 07-Feb, the stock price of Fortis Malar Hospitals Ltd is currently at 56.19, reflecting a 1.46% increase today. Despite this short-term rise, the stock has faced declines over the past month and year, and decreasing investor participation may indicate potential challenges ahead.

As of 07-Feb, the stock price of Fortis Malar Hospitals Ltd is rising, currently at 56.19, with a change of 0.81 (1.46%) upward. This increase is notable as it has outperformed its sector by 1.39% today. However, it is important to consider the broader context of the stock's performance. Over the past week, the stock has shown a slight increase of 0.81%, while it has experienced declines over longer periods, such as a 4.55% drop over the past month and a 6.12% decrease over the past year. <BR><BR>Additionally, the stock's moving averages indicate that it is currently higher than its 5-day moving average but lower than its 20-day, 50-day, 100-day, and 200-day moving averages, suggesting mixed performance trends. Furthermore, there has been a significant decrease in investor participation, with delivery volume falling by 37.51% against the 5-day average, which may indicate a lack of strong buying interest despite the current rise in price. Overall, while the stock is experiencing a rise today, its longer-term performance and declining investor participation could suggest underlying challenges.